Basic Information
| LncRNA/CircRNA Name | LSINCT5 |
| Synonyms | NA |
| Region | GRCh38_5:2712591-2715237 |
| Ensemble | |
| Refseq | NR_145480 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | osteosarcoma |
| ICD-0-3 | NA |
| Methods | RNAi, qPCR, other |
| Sample | OS tissues and cell lines (Saos-2, U2OS, MG-63, and 143B) |
| Expression Pattern | up-regulated |
| Function Description | LSINCT5 was significantly upregulated in OS tissues than in adjacent normal tissues. Additionally, the expression of LSINCT5 was inversely associated with the prognosis of patients with OS. LSINCT5 knockdown dramatically inhibited OS cell proliferation in vitro and tumor growth in vivo. Mechanistic exploration revealed that LSINCT5 interacted with EZH2 to suppress the expression of APC, a negative regulator of the Wnt/?-catenin pathway. Moreover, rescue assays suggested that LSINCT5 exerted oncogenic roles by partially inhibiting APC expression in OS. |
| Pubmed ID | 30420287 |
| Year | 2018 |
| Title | Long Noncoding RNA LSINCT5 Acts as an Oncogene via Increasing EZH2-induced Inhibition of APC Expression in Osteosarcoma |
External Links
| Links for LSINCT5 | GenBank HGNC NONCODE |
| Links for osteosarcoma | OMIM COSMIC |